SCHEMBL3772157

SCHEMBL3772157

CC(C)N1CCN(C(=O)CN2CCN(c3ccc4c(c3)OCO4)CC2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.51
KDM4E B2RXH2 4/20 0.51
TDP1 Q9NUW8 2/20 0.51
HTT P42858 1/20 0.51
MAPT P10636 5/20 0.50
MAPK1 P28482 1/20 0.50
PKM P14618 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
KMT2A Q03164 4/20 0.47
GAA P10253 2/20 0.46
LMNA P02545 2/20 0.46
MEN1 O00255 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
THRB P10828 1/20 0.45
ALOX15 P16050 1/20 0.45
ALOX12 P18054 1/20 0.45
TSHR P16473 3/20 0.45
GFER P55789 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3773777 0.81 ALDH1A1 (0.52) ALDH1A1KDM4ETDP1HTTMAPT
SCHEMBL3763190 0.81 RAB9A (0.58) ALDH1A1HTTMAPTMAPK1PKM
SCHEMBL3773911 0.81 KMT2A (0.55) ALDH1A1KDM4EMAPTMAPK1KMT2A
SCHEMBL3765110 0.81 KMT2A (0.53) ALDH1A1KDM4EMAPTMAPK1KMT2A
SCHEMBL3776078 0.80 MAPT (0.59) ALDH1A1KDM4ETDP1HTTMAPT
SCHEMBL25122016 0.79 PKM (0.60) ALDH1A1KDM4ETDP1HTTMAPT
SCHEMBL3768057 0.79 MAPT (0.58) ALDH1A1KDM4ETDP1MAPTPKM
SCHEMBL3769115 0.79 SMN1; SMN2 (0.71) ALDH1A1KDM4EMAPTPKMNPSR1
SCHEMBL3771806 0.79 ALDH1A1 (0.58) ALDH1A1KDM4ETDP1MAPTMAPK1
SCHEMBL26171578 0.79 PKM (0.60) ALDH1A1KDM4ETDP1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ALDH1A1 1210/4885KDM4E 534/4885TDP1 4483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.